研究单位：[1]Head of the cancer center,Huazhong University of Science and Technology[2]Tongji hospital of Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030
研究目的：
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
